医学
支气管扩张
哮喘恶化
免疫学
内科学
哮喘
肺
作者
Raquel Viana,João Cordeiro da Costa,Elisabete Gomes,Salvato Feijó
出处
期刊:European Respiratory Journal
日期:2019-09-28
卷期号:: PA2873-PA2873
被引量:2
标识
DOI:10.1183/13993003.congress-2019.pa2873
摘要
Introduction: Eosinophils (eos) count are related to inhaled corticosteroids response in exacerbator phenotype in COPD. The main goal of this work was to test the hypothesis of the relationship between peripheral blood eosinophil count and bronchiectasis exacerbations. Methods: Retrospective cohort study. Patients followed in a specialized bronchiectasis consultation in Centro Hospitalar de Leiria (Portugal) were consecutively included from 01/2017 to 01/2019. Patients on chronic oral steroids were excluded. Peripheral blood eosinophils count at beginning of the study was compared. Patients were divided into 2 groups: G1 (≥300eos/ul) and G2 (<300eos/ul). Lung function, exacerbations, inhaled corticosteroids and microbiological profile were compared. Central tendency measures, chi-square/Fisher exact test and T test were used appropriately. IBM® SPSS vr24 was used. Statistical significance was determined to p<0.05. Results: 94 patients were included, 30 in G1 (10% females, mean age 60.3±16.1years) and 64 in G2 (56.3% females, mean age 63.5±16years) (p=0.038/p=0.381 for sex/age respectively). There were no significant differences in the prevalence of asthma, COPD, diffuse lung disease, emphysema, Pseudomonas aeruginosa, Haemophilus influenza and inhaled corticosteroids between groups. The mean number of exacerbations was similar in 2017 (1.68±1.68 vs 1.15±1.90, p=0.223) and 2018 (0.61±0.99 vs 1.21±1.96, p=0.067) between groups G1 and G2 respectively. There were no significant difference in the number of exacerbations controlling for inhaled corticosteroids therapy. Lung function was similar in both groups. Conclusions: Eosinophils count was not related to exacerbations in this bronchiectasis cohort.
科研通智能强力驱动
Strongly Powered by AbleSci AI